Clinical Report: Second RSV vaccine dose shows comparable antibody response
Overview
A second dose of Moderna’s mRNA-1345 RSV vaccine, administered 24 months after the primary dose, produced neutralizing antibody responses that met noninferiority criteria compared to the primary vaccination. The phase 3 study included 1,502 adults aged 60 years or older.
Background
Respiratory syncytial virus (RSV) poses significant health risks, particularly for older adults. Understanding the efficacy and safety of revaccination can inform clinical practices and guidelines for older populations.
Data Highlights
| Parameter | Results |
|---|---|
| Participants | 1,502 |
| Vaccine Group | 998 |
| Placebo Group | 504 |
| Neutralizing Antibody Response (RSV-A and RSV-B) | Noninferior to primary dose |
| Solicited Reactions | Mild to moderate |
| Serious Adverse Events | Infrequent and unrelated to vaccine |
Key Findings
- Revaccination with mRNA-1345 was well tolerated in adults aged ≥60 years.
- Neutralizing antibody responses after revaccination met noninferiority criteria compared to primary vaccination.
- Most solicited reactions were mild or moderate, similar to those observed after the primary dose.
- Serious adverse events were infrequent and not related to the vaccine.
- Immune responses were consistent across demographic and clinical subgroups.
Clinical Implications
The findings suggest that revaccination with mRNA-1345 can effectively boost neutralizing antibody levels in older adults without significant safety concerns. Clinicians should consider the potential for revaccination strategies in managing RSV risk in this population.
Conclusion
This study supports the safety and immunogenicity of a second dose of mRNA-1345 in older adults.
Related Resources & Content
- Moderna, The Journal of Infectious Diseases, 2026 -- Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 RSV Vaccine
- Reuters, 2026 -- RSV Vaccine Effective in Immunocompromised Adults: Study
- The ASCO Post, 2025 -- Immunogenicity of RSV Vaccines in Immunocompromised Allogeneic HSCT Recipients
- Reuters, 2026 -- Moderna Reports 50% Efficacy for RSV Vaccine in Second Season
- CDC, 2024 -- Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations
- New England Journal of Medicine, 2023 -- Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults
- PubMed, 2026 -- Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 RSV Vaccine
- Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults | New England Journal of Medicine
- Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 RSV Vaccine Administered 24 Months Following a Primary Dose in Adults ≥60 Years of Age - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
